Christopher M. Hix

October 9, 2026

JP Morgan Lowers Middleby Target to $145 While Maintaining Overweight. JP Morgan keeps an overweight rating on Middleby but cut its price target to $145 from higher levels. The new target sits below the current 52‑week high of $148.55 and near the analyst average of $155.67. With an RSI of 36.4, the stock is not yet oversold and is near a support level of $110.83. The downgrade may influence short‑term sentiment while the company remains valued at a 17.3 P/E.

October 10, 2026

Brady Corp Highlights Investor Appeal, 2026 Synergy Targets and Dividend Growth. Brady’s latest news shows why investors are attracted to the company, citing its strong fundamentals and growth prospects. The firm plans to integrate its PSS business by 2026, aiming for $25 million in annual synergies. In addition, Brady is among a group of dividend‑growth companies expected to raise dividends this October. These developments underscore the company’s focus on value creation and shareholder returns.

October 8, 2026

ESAB Schedules Q3 2026 Earnings Call Amid Mixed Stock Performance. ESAB has announced the schedule for its third-quarter 2026 earnings release and conference call. This announcement follows a period of mixed price action, with recent reports noting both sharp declines and significant gains in the stock. The company is preparing to share updated financial results as investors monitor its performance against a 52-week range of $64.83 to $137.42.

September 25, 2026

Enovis joins AAOS Registry Program as industry sponsor. Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.